What We Do
Inflection’s pipeline programs were licensed from the Spanish National Cancer Research Centre (CNIO) following an extensive global in-licensing process. The CNIO has a global reputation for excellence in cancer research and has its own drug discovery program.
The pipeline comprises of IBL-202, selected from a series of unique dual mechanism kinase inhibitors, the IBL-100 series, pan-PIM inhibitors currently in preclinical stages of development and AUM302 (formerly IBL-302), partnered with AUM Biosciences. Kinase inhibitors are an important new class of targeted therapy that modify specific cell signalling pathways that are involved in cancer disease processes. Kinase inhibitors are a highly successful class of novel treatments for cancer and have shown lower attrition rates as they advance through clinical development.